FDA approves vorasidenib for Grade 2 gliomas with IDH mutations Vorasidenib is approved by the U.S. Food and Drug Administration (FDA) for patients with grade 2 gliomas with IDH1 or…
FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment On July 29, 2024, the US FDA approved Alpha Cognition Inc.’s ALPHA-1062 (Zunveyl).®), an Acetylcholinesterase (AChE) inhibitor, for the treatment…
